The United States Adopted Name Council, which selects simple, new, and informative generic drug names, has approved ‘Onvansertib’ as the generic name for PCM-075. PCM-075 is an investigational drug that is being researched as a potential treatment for acute myeloid leukaemia and metastatic castration-resistant prostate cancer. For more detailed information, you can view the original press release here, at PR Newswire.
About Acute Myeloid Leukaemia
Acute myeloid leukaemia is an aggressive form of cancer that affects a type of white blood cell called myeloid cells, which play an important role in fighting bacterial infections and parasites and preventing tissue damage spread. People with acute myeloid leukaemia tend to produce too many immature white blood cells (blast cells), which can cause the number of red blood cells and platelets in the blood to fall.
About Prostate Cancer
Prostate cancer is one of the most common forms of cancer in men worldwide. The prostate is a small gland in the pelvis found in males. According to the NHS, prostate cancer is often associated with few symptoms until it grows large enough to affect the urethra. At this point, people with the condition may experience symptoms such as a frequent need to urinate, straining during urination, and feeling as though the bladder hasn’t completely emptied.
About Onvansertib
Onvansertib (PCM-075) is a 3rdgeneration oral drug that works by selectively inhibiting PLK1 (Polo Like Kinase 1). Onvansertib may also be able to work synergistically with other existing treatments, meaning that the effects of the two drugs combined add up to more than the sum of their effectiveness. According to the source press release, PLK1 is over-expressed in several forms of cancer, and previous research into PLK inhibitors has suggested that inhibiting PLK enzymes may be linked to tumour cell death. Onvansertib has been awarded Orphan Drug status for the treatment of acute myeloid leukaemia by the US Food and Drug Administration and by the EMA in the European Union and there are plans to further investigate the drug in upcoming clinical trials.
For more information about the drug and related research, you can view the original press release by clicking here.
